Q32 Bio raises $10.5 million in registered direct offering

Q32 Bio Inc. (NASDAQ: QTTB) announced a $10.5 million registered direct offering led by a new institutional investor with participation from an existing institutional investor.

The biotechnology company entered into a definitive agreement to issue 1,666,679 shares of common stock and pre-funded warrants to purchase up to 1,025,654 shares of common stock. The offering price is $3.90 per share of common stock, matching the closing price on February 13, 2026, and $3.8999 per pre-funded warrant.

The pre-funded warrants are immediately exercisable at $0.0001 per share and may be exercised at any time until fully exercised. The offering is expected to close on or about February 18, 2026, subject to customary closing conditions.

Q32 Bio intends to use the net proceeds, together with existing cash, cash equivalents and marketable securities, for working capital purposes including research, clinical development and commercialization efforts. The funds will support the advancement of bempikibart into future clinical trials for treating alopecia areata.

The securities are being offered under a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on April 11, 2025, and declared effective on April 21, 2025.

Q32 Bio is a clinical stage biotechnology company developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The company is advancing bempikibart, a fully human anti-IL-7Rα antibody, in an ongoing Phase 2 program for alopecia areata treatment.

You May Also Be Interested In

• Wrap Technologies closes $12M stock offering at $1.40 per share
• Dynatrace prices $1.25B exchangeable senior notes due 2031
• Charter Communications closes $4.75 billion senior secured notes offering